Product logins

Find logins to all Clarivate products below.


Hypertension | Current Treatment: Physician Insights | US | 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different classes. Nevertheless, despite the numerous treatment options, significant unmet need remains in the treatment of resistant hypertension, which is defined as inadequately controlled BP despite the concurrent use of three or more antihypertensive agents. This report provides cardiologist insight into prescribing patterns for hypertension and especially resistant hypertension.

Questions Answered:

  • What patient shares do angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) garner in the U.S. hypertension market? What are the trends in prescribing for resistant hypertension?
  • How do physicians diagnose resistant hypertension, and how does this diagnosis influence their treatment approach?
  • What factors constrain and what factors drive choice of hypertension treatment?
  • What percentage of hypertensive patients receive monotherapy versus combination therapy?

Product Description:

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 100 U.S. cardiologists

KEY DRUGS COVERED: ACE inhibitors, ARBs, diuretics, calcium channel blockers, beta blockers, aldosterone antagonists, mineralocorticoid receptor antagonists (MRAs), diuretics, direct renin inhibitors, centrally acting antihypertensives, and alpha blockers.

KEY INSIGHTS PROVIDED: Factors influencing disease management and treatment decisions; drivers of and constraints on treatment selection; physician-reported treatment practices; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent/anticipated changes in treatment approach.

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)
Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…